| Excerpt | Relevance | Reference |
|---|
| "Although gemcitabine plus cisplatin is the gold standard chemotherapy regimen for advanced cholangiocarcinoma, the response rate has been disappointing." | 7.88 | Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. ( Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC, 2018) |
| "Although gemcitabine plus cisplatin is the gold standard chemotherapy regimen for advanced cholangiocarcinoma, the response rate has been disappointing." | 3.88 | Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. ( Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC, 2018) |